Scott Galasinski has worked in both biotech and pharma, including Head of BioPharmaceuticals Business Development at AstraZeneca, Head of Ultra-rare gene therapies at Novartis (previously Avexis), Executive Director at Ultragenyx, and group leader for many teams at Abbvie (previously Abbott labs). 

He earned his Ph.D. at the University of Colorado, Boulder.  He has worked across many different therapeutic areas, and across many different therapeutic modalities including small molecules, biologics, AAV gene therapy, and nucleic acids.  Scott likes to work with both science and business teams to find creative solutions to move medicines forward for diseases with unmet need.